485 related articles for article (PubMed ID: 29914442)
21. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
22. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
23. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
24. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
Yao Y; Dou C; Lu Z; Zheng X; Liu Q
Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
26. HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway.
Li M; Tan T; Geng Y; Tao Y; Pan J; Zhang J; Xu Q; Shen H; Zuo L; Chen Y
Ann Hepatol; 2023; 28(1):100759. PubMed ID: 36179794
[TBL] [Abstract][Full Text] [Related]
27. ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling.
Xie B; Zen Q; Wang X; He X; Xie Y; Zhang Z; Li H
Int J Oncol; 2015 May; 46(5):2057-66. PubMed ID: 25738261
[TBL] [Abstract][Full Text] [Related]
28. Pivotal role of mTOR signaling in hepatocellular carcinoma.
Villanueva A; Chiang DY; Newell P; Peix J; Thung S; Alsinet C; Tovar V; Roayaie S; Minguez B; Sole M; Battiston C; Van Laarhoven S; Fiel MI; Di Feo A; Hoshida Y; Yea S; Toffanin S; Ramos A; Martignetti JA; Mazzaferro V; Bruix J; Waxman S; Schwartz M; Meyerson M; Friedman SL; Llovet JM
Gastroenterology; 2008 Dec; 135(6):1972-83, 1983.e1-11. PubMed ID: 18929564
[TBL] [Abstract][Full Text] [Related]
29. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
30. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
31. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
32. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
[TBL] [Abstract][Full Text] [Related]
33. Celastrus orbiculatus Extracts Inhibit Human Hepatocellular Carcinoma Growth by Targeting mTOR Signaling Pathways.
Qian YY; Li WY; Yan Y; Zhao XY; Yang T; Fang CC; Hou JJ; Liu YQ
Chin J Integr Med; 2019 Nov; 25(11):845-852. PubMed ID: 31127506
[TBL] [Abstract][Full Text] [Related]
34. mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development.
Feng J; Guo J; Zhao P; Shen J; Chai B; Wang J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32420585
[TBL] [Abstract][Full Text] [Related]
35. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.
Zheng H; Jiang WH; Tian T; Tan HS; Chen Y; Qiao GL; Han J; Huang SY; Yang Y; Li S; Wang ZG; Gao R; Ren H; Xing H; Ni JS; Wang LH; Ma LJ; Zhou WP
Oncotarget; 2017 Mar; 8(12):18872-18884. PubMed ID: 28122351
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.
Zhao Y; Li F; Zhang X; Liu A; Qi J; Cui H; Zhao P
Int J Clin Exp Pathol; 2015; 8(10):12446-54. PubMed ID: 26722431
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
38. STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer.
Wu F; Gao P; Wu W; Wang Z; Yang J; Di J; Jiang B; Su X
J Exp Clin Cancer Res; 2018 Jul; 37(1):144. PubMed ID: 29996891
[TBL] [Abstract][Full Text] [Related]
39. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
40. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.
Hsieh YH; Hsieh SC; Lee CH; Yang SF; Cheng CW; Tang MJ; Lin CL; Lin CL; Chou RH
Oncotarget; 2015 Oct; 6(33):34859-74. PubMed ID: 26472188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
